Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Arrowhead Pharmaceuticals Corp (ARWR) May Be Worth $75-$90 in a Sale - Cantor Fitzgerald
November 26, 2019 1:44 PM ESTCantor Fitzgerald analyst Alethia Young said Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) may be worth $75-$90 in a sale. The analyst reiterated a Neutral rating and $50 price target.
... MoreArrowhead Pharmaceuticals Corp (ARWR) Q4 Revs Beat
November 25, 2019 4:20 PM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $43.29 million versus the consensus estimate of $41.48 million.
Fiscal Year 2019 revenue was $168.796 million, EPS was $0.69.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More